Pilot-scale process development for recombinant adeno-associated virus (rAAV) production based on high-density Sf9 cell culture
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Pilot-scale process development for recombinant adeno-associated virus (rAAV) production based on high-density Sf9 cell culture ; volume:21 ; number:1 ; day:7 ; month:11 ; year:2024 ; pages:1-10 ; date:12.2024
Virology journal ; 21, Heft 1 (7.11.2024), 1-10, 12.2024
- Urheber
-
Li, Xinran
Gu, Jieyi
Wu, Haoquan
Xie, Yuanyuan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12985-024-02550-4
- URN
-
urn:nbn:de:101:1-2501252120098.535385650228
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Xinran
- Gu, Jieyi
- Wu, Haoquan
- Xie, Yuanyuan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Molecular design for recombinant adeno-associated virus (rAAV) vector production
Adeno-Associated Virus (AAV) vectors in gene therapy
Adeno‐associated virus (AAV)-based gene therapy for glioblastoma
Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Adeno-associated virus display : in vitro evolution of AAV retargeted vectors
Enhanced recombinant adeno-associated virus (rAAV) in vivo transduction efficacy via surface modified PAMAM nanoparticles precoating
Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein–Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV + lymphoproliferative disorders
Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors
Incorporation of tumor-targeting peptides into recombinant Adeno-associated virus capsids
Enhanced β2-adrenergic receptor (β2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Molecular design for recombinant adeno-associated virus (rAAV) vector production
Adeno-Associated Virus (AAV) vectors in gene therapy
Adeno‐associated virus (AAV)-based gene therapy for glioblastoma
Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Adeno-associated virus display : in vitro evolution of AAV retargeted vectors
Enhanced recombinant adeno-associated virus (rAAV) in vivo transduction efficacy via surface modified PAMAM nanoparticles precoating
Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein–Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV + lymphoproliferative disorders
Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors
Incorporation of tumor-targeting peptides into recombinant Adeno-associated virus capsids
Enhanced β2-adrenergic receptor (β2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Molecular design for recombinant adeno-associated virus (rAAV) vector production
Adeno-Associated Virus (AAV) vectors in gene therapy
Adeno‐associated virus (AAV)-based gene therapy for glioblastoma
Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Adeno-associated virus display : in vitro evolution of AAV retargeted vectors
Enhanced recombinant adeno-associated virus (rAAV) in vivo transduction efficacy via surface modified PAMAM nanoparticles precoating
Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein–Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV + lymphoproliferative disorders
Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors
Incorporation of tumor-targeting peptides into recombinant Adeno-associated virus capsids